Outcomes of Adjunctive Therapy with Intravenous Cefoperazone-Sulbactam for Ventilator-Associated Pneumonia Due to Carbapenem-Resistant Acinetobacter baumannii

References

• Magill SS, Edwards JR, Bamberg W, et al. Emerging infections program healthcare-associated infections and antimicrobial use prevalence survey team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198–1208. doi:10.1056/NEJMoa130680124670166
   PubMed Web of Science ®Google Scholar
• Muscedere JG, Day A, Heyland DK. Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia. Clin Infect Dis. 2010;51(S1):S120–S125. doi:10.1086/65306020597661
   PubMed Web of Science ®Google Scholar
• Antunes L, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis. 2014;71(3):292–301. doi:10.1111/2049-632X.1212524376225
   PubMed Web of Science ®Google Scholar
• Asif M, Alvi IA, Rehman SU. Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect Drug Resist. 2018;11:1249. doi:10.2147/IDR.S16675030174448
   PubMed Web of Science ®Google Scholar
• Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943–4960. doi:10.1128/AAC.00296-1121859938
   PubMed Web of Science ®Google Scholar
• Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria. Clin Infect Dis. 2019;69(Supplement_7):S521–S528. doi:10.1093/cid/ciz82431724045
   PubMed Web of Science ®Google Scholar
• Kengkla K, Kongpakwattana K, Saokaew S, Apisarnthanarak A, Chaiyakunapruk N. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother. 2018;73(1):22–32. doi:10.1093/jac/dkx36829069421
   PubMed Web of Science ®Google Scholar
• Jones RN, Barry AL. Cefoperazone: a review of its antimicrobial spectrum, β-lactamase stability, enzyme inhibition, and other in vitro characteristics. Rev Infect Dis. 1983;5(Supplement_1):S108–S126. doi:10.1093/clinids/5.Supplement_1.S1086221381
   PubMedGoogle Scholar
• Akova M. Sulbactam-containing β-lactamase inhibitor combinations. Clin Microbiol Infect. 2008;14:185–188. doi:10.1111/j.1469-0691.2007.01847.x18154545
   PubMed Web of Science ®Google Scholar
• Leelasupasri S, Santimaleeworagun W, Jitwasinkul T. Antimicrobial susceptibility among colistin, sulbactam, and fosfomycin and a synergism study of colistin in combination with sulbactam or fosfomycin against clinical isolates of carbapenem-resistant Acinetobacter baumannii. J Pathog. 2018;2018:1–5. doi:10.1155/2018/3893492
   Web of Science ®Google Scholar
• Rodríguez-Hernández M-J, Cuberos L, Pichardo C, et al. Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J Antimicrob Chemother. 2001;47(4):479–482. doi:10.1093/jac/47.4.47911266426
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Gotfried MH, Isaacs RD, O’Donnell JP, Stone E. Plasma and intrapulmonary concentrations of ETX2514 and sulbactam following intravenous administration of ETX2514SUL to healthy adult subjects. Antimicrob Agents Chemother. 2018;62(11). doi:10.1128/AAC.01089-18
   Web of Science ®Google Scholar
• Wildfeuer A, Rühle K, Bölcskei P, Springsklee M. Concentrations of ampicillin and sulbactam in serum and in various compartments of the respiratory tract of patients. Infection. 1994;22(2):149–151. doi:10.1007/BF17390278070929
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Matsumoto K, Ikawa K, et al. Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models. Int J Antimicrob Agents. 2014;43(6):547–552. doi:10.1016/j.ijantimicag.2014.02.01224796218
   PubMed Web of Science ®Google Scholar
• Woodford N, Ellington MJ, Coelho JM, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2006;27(4):351–353. doi:10.1016/j.ijantimicag.2006.01.00416564159
   PubMed Web of Science ®Google Scholar
• La Scola B, Gundi VA, Khamis A, Raoult D. Sequencing of the rpoB gene and flanking spacers for molecular identification of Acinetobacter species. J Clin Microbiol. 2006;44(3):827–832. doi:10.1128/JCM.44.3.827-832.200616517861
   PubMed Web of Science ®Google Scholar
• Wayne P. Clinical and Laboratory Standards Institute: performance standards for antimicrobial susceptibility testing: 20th informational supplement. CLSI Document M100-S20. 2010.
   Google Scholar
• Alsoud RA, Svensson RJ, Svensson EM, et al. Simultaneous assessment of time-to-positivity and colony-forming unit in tuberculosis patients under high-dose rifampicin therapy. PAGE2019 Poster Abstracts. 59.
   Google Scholar
• Barry AL, Jones RN. Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination. J Clin Microbiol. 1988;26(1):13–17. doi:10.1128/JCM.26.1.13-17.19883343304
   PubMed Web of Science ®Google Scholar
• Kellum JA, Bellomo R, Ronco C. Definition and classification of acute kidney injury. Nephron Clin Pract. 2008;109(4):c182–c187. doi:10.1159/00014292618802365
   PubMedGoogle Scholar
• Karvanen M, Plachouras D, Friberg LE, et al. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother. 2013;57(1):668–671. doi:10.1128/AAC.00985-1223147733
   PubMed Web of Science ®Google Scholar
• Vila J, Pachón J. Therapeutic options for Acinetobacter baumannii infections: an update. Expert Opin Pharmacother. 2012;13(16):2319–2336. doi:10.1517/14656566.2012.72982023035697
   PubMed Web of Science ®Google Scholar
• Chaari A, Mnif B, Bahloul M, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors. Int J Infect Dis. 2013;17(12):e1225–e1228. doi:10.1016/j.ijid.2013.07.01424094525
   PubMed Web of Science ®Google Scholar
• Hurley JC. World-wide variation in incidence of Acinetobacter associated ventilator associated pneumonia: a meta-regression. BMC Infect Dis. 2016;16(1):577. doi:10.1186/s12879-016-1921-427756238
   PubMed Web of Science ®Google Scholar
• Lim SMS, Abidin AZ, Liew S, Roberts J, Sime F. The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: a systematic review and meta-analysis. J Infect. 2019;79(6):593–600. doi:10.1016/j.jinf.2019.09.01231580871
   PubMed Web of Science ®Google Scholar
• Harris BD, Thomas GA, Greene MH, Spires SS, Talbot TR. Ventilator bundle compliance and risk of ventilator-associated events. Infect Control Hosp Epidemiol. 2018;39(6):637–643. doi:10.1017/ice.2018.3029770752
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang S, Chen J, et al. Risk factors for ventilator-associated events: a prospective cohort study. Am J Infect Control. 2019;47(7):744–749. doi:10.1016/j.ajic.2018.09.03230584021
   PubMed Web of Science ®Google Scholar
• Dickstein Y, Lellouche J, Ben Dalak Amar M, et al. Treatment outcomes of colistin-and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a randomized clinical trial. Clin Infect Dis. 2019;69(5):769–776. doi:10.1093/cid/ciy98830462182
   PubMed Web of Science ®Google Scholar
• Piperaki E-T, Tzouvelekis L, Miriagou V, Daikos G. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin Microbiol Infect. 2019;25(8):951–957. doi:10.1016/j.cmi.2019.03.01430914347
   PubMed Web of Science ®Google Scholar
• Russo A, Bassetti M, Ceccarelli G, et al. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study. J Infect. 2019;79(2):130–138. doi:10.1016/j.jinf.2019.05.01731145911
   PubMed Web of Science ®Google Scholar
• Nation RL, Garonzik SM, Li J, et al. Updated US and European dose recommendations for intravenous colistin: how do they perform? Clin Infect Dis. 2016;62(5):552–558. doi:10.1093/cid/civ96426607424
   PubMed Web of Science ®Google Scholar
• Jaruratanasirikul S, Nitchot W, Wongpoowarak W, Samaeng M, Nawakitrangsan M. Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii. Eur J Pharm Sci. 2019;136:104940. doi:10.1016/j.ejps.2019.05.01831132402
   PubMed Web of Science ®Google Scholar
• Li J, Yang X, Chen L, Duan X, Jiang Z. In Vitro activity of various antibiotics in combination with tigecycline against Acinetobacter baumannii: a systematic review and meta-analysis. Microb Drug Resist. 2017;23(8):982–993. doi:10.1089/mdr.2016.027928437233
   PubMed Web of Science ®Google Scholar
• Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/pharmacodynamic profile for tigecycline—a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis. 2005;52(3):165–171. doi:10.1016/j.diagmicrobio.2005.05.00616105560
   PubMed Web of Science ®Google Scholar
• Pournaras S, Koumaki V, Gennimata V, Kouskouni E, Tsakris A. In vitro activity of tigecycline against Acinetobacter baumannii: global epidemiology and resistance mechanisms. Adv Microbiol Infect Dis Public Health. 2015;1–14.
   Google Scholar